CRP and hematopoietic and lymphoid cell neoplasm: Conversely, biochemical analysis showed augmented levels of CRP and D-dimer in the Severe-Death hematologic cancer patients as compared to the Mild group (Figure 2C), whereas none of the hematological or biochemical parameters differed between solid tumor patients with distinct clinical outcomes (Figures 2A–C).